US

For Days inks $2.8 mln seed funding

For Days, a fully closed-loop clothing line, has raised $2.8 million in seed funding. Rosecliff Ventures led the round with participation from Collaborative Fund, Congruent Ventures, Third Prime Capital, Closed Loop Ventures, Bleu Capital, Gramercy Fund and Ride Ventures.

Resolute Ventures to raise $75 mln venture-capital fund

Resolute Ventures has set out to raise a $75 million fourth venture-capital fund, according to a filing with the SEC.

Ex KP's Michael Linse to raise $65 mln venture fund

Linse Capital has set out to raise $65 million for a venture-capital fund, according to a filing with the SEC.

Israeli tech startup Guardian Optical Technologies gathers $2.5 mln

Tel Aviv-based Guardian Optical Technologies, a tech startup, has secured $2.5 million in funding. The investors included Union Ventures and B&E Equities.

Design platform provider Framer attracts $24 mln Series B

Amsterdam-based Framer, a provider of an interactive design platform, has secured $24 million in Series B funding. Atomico led the round.

Emotion AI startup Looxid Labs grabs $4 mln Series A

Seoul, South Korea-based Looxid Labs, an emotion AL startup, has secured $4 million in Series A funding. Hastings Asset Management, Daesung Private Equity, Sejong Venture Partners and Samsung Venture investment were the lead investors.

UK property startup Nested inks funding

UK-based property startup Nested has raised 120 million pounds in funding. The investors included Northzone and Balderton Capital.

AEGEA Medical fetches $17 mln

Menlo Park, California-based AEGEA Medical Inc, a medical device company, has raised $17 million in financing. Solas BioVentures led the round.

Spin Memory pulls in $52 mln Series B

Fremont, California-based Spin Memory, a MRAM developer formerly known as Spin Transfer Technologies Inc, has secured $52 million in Series B funding. Applied Ventures LLC led the round.

Harpoon Therapeutics snags $70 mln Series C

South San Francisco-based Harpoon Therapeutics Inc, a clinical-stage immunotherapy company, has raised $70 million in Series C financing. OrbiMed led the round with participation from other investors that included Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures, NS Investment, MPM Capital, Oncology Impact Fund, Arix Bioscience, New Leaf Venture Partners and Taiho Ventures LLC.